Prognostic value of STC1 in solid tumors: a meta-analysis

Abstract

Aim: The prognostic value of STC1 has been evaluated in solid tumors. However, the results remain controversial. Materials & methods: Relevant studies published up to 27 February 2021 were identified by a comprehensive search of the PubMed, EMBASE and Web of Science databases. Hazard ratios (HRs) and odds ratios with 95% CIs were applied to explore the association between STC1 and survival outcome and clinical characteristics. Results: Sixteen articles involving 2942 participants were included in this meta-analysis. The pooled analysis showed that high STC1 expression was significantly associated with worse overall survival (HR: 1.91; 95% CI: 1.63–2.24) and disease-free survival/progression-free survival/relapse-free survival (HR: 2.01; 95% CI: 1.34–3.02). Conclusion: STC1 may be an effective prognostic marker in solid tumors.